Comparison of intravitreal ranibizumab and aflibercept in patients with choroidal neovascularization in pathologic myopia
DOI:
https://doi.org/10.31288/oftalmolzh201753438Keywords:
pathologic myopia, choroidal neovascularization, ranibisumab and afliberceptAbstract
Purpose. To compare the efficacy of ranibizumab and aflibercept treatment of patients with choroidal neovascularization (CNV) in pathologic myopia.
Material and Methods. This was a comparative, uncontrolled, prospective cohort study, enrolling 96 pathologic myopic eyes (93 patients) with subretinal neovascularization.
Results. 65 eyes (63 patients) were treated with 0.5 mg intravitreal ranibizumab; 31 eyes (30 patients) were treated by 2 mg intravitreal aflibercept. The baseline mean visual acuity was 0.2 and 0.21 in the intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) groups, respectively. At 12 months, the mean visual acuity was 0.4 and 0.37 for the IVR and IVA groups, respectively. The mean CRT at baseline was 314.6 µm and 276.5 µm for the IVR and IVA groups, respectively. At 12 months, the mean CRT was 226.7 µm (р = 0.000) and 224.3 µm (р = 0.000) for the IVR and IVA groups, respectively. The mean number of injections in the IVR and IVA groups was 2.3 (0.9) and 2.6 (0.9), respectively. No statistically significant difference was noted in the number of injections between groups (р = 0.15).
Conclusions. Both ranibisumab and aflibercept were found to improve the visual acuity in pathologic myopic patients with CNV with no statistically significant difference in the number of intravitreal injections.
References
1.Medvedev IB, Belikova EI, Syamichev M.P. [Photodynamic therapy in ophthalmology]. OOO "GUPT "Krasnyi voin""; 2006. 152 p. In Russian.
2.Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial FVIP report no. 3. Ophthalmology. 2003; 110:667-673.https://doi.org/10.1016/S0161-6420(02)01998-X
3.Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117:1124-1133.https://doi.org/10.1016/j.ophtha.2010.02.022
4.Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009; 116:57-65.https://doi.org/10.1016/j.ophtha.2008.10.018
5.Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117:1102-1112.https://doi.org/10.1016/j.ophtha.2010.02.021
6.Cha DM, Kim TW, Heo JW, et al. Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study.BMC Ophthalmology. 2014; 14:69.https://doi.org/10.1186/1471-2415-14-69
7.Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996; 103:1241-1244.https://doi.org/10.1016/S0161-6420(96)30515-0
8.Cornut PL , Poli M , Feldman A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmology. 2010; 33(5):327-333.https://doi.org/10.1016/j.jfo.2010.03.006
9.Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology.2012; 119:2537-2548.https://doi.org/10.1016/j.ophtha.2012.09.006
10.Heier JS, Clark WL, Boyer DS et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014; 121:1414-1420.https://doi.org/10.1016/j.ophtha.2014.01.027
11.Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology.2014; 121:2247-2254.https://doi.org/10.1016/j.ophtha.2014.05.006
12.Lai TY, Chan WM, Liu DT, et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009; 29:750-756.https://doi.org/10.1097/IAE.0b013e31819ed6bd
13.Mon?s JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond). 2009; 23(6):1275-1280.https://doi.org/10.1038/eye.2009.88
14.Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119:789-801.https://doi.org/10.1016/j.ophtha.2011.12.039
15.Ogura Y, Roider J, Korobelnik JF, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol.2014; 158:1032-1038.https://doi.org/10.1016/j.ajo.2014.07.027
16.Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol.2003;87:570-573.https://doi.org/10.1136/bjo.87.5.570
17.Ozdek S, Hondur A, Gurelik G, et al. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up International Ophthalmology. 2005; 26(4-5):127-133.https://doi.org/10.1007/s10792-006-9010-0
18.Pasyechnikova NV, Naumenko VO, Korol AR, et al. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study. Ophthalmologica. 2015; 233(1):2-7.https://doi.org/10.1159/000369397
19.Pece A, Milani P. Intravitreal aflibercept for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2016 Dec; 254 (12):2327-32.https://doi.org/10.1007/s00417-016-3396-9
20.Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419-1431.https://doi.org/10.1056/NEJMoa054481
21.Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010; 30: 407-412.https://doi.org/10.1097/IAE.0b013e3181c9691e
22.Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013; 120:1944-1945.https://doi.org/10.1016/j.ophtha.2013.06.010
23.Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond).2013; 27:709-715.https://doi.org/10.1038/eye.2013.8
24.Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularization in pathologic myopia. Cochrane Database Syst Rev.2005; (4):CD004765.https://doi.org/10.1002/14651858.CD004765.pub2
25.Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology.2014;121:682-692.https://doi.org/10.1016/j.ophtha.2013.10.023
26.Wu TT, Kung YH. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther. 2012; 28(2):129-133.https://doi.org/10.1089/jop.2011.0106
27.Yasushi Ikuno, Kyoko Ohno-Matsui, Tien Yin Wong, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization The MYRROR Study. Ophthalmology.2015; 122: 1220-1227.https://doi.org/10.1016/j.ophtha.2015.01.025
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 О. М. Блавацька, Т. Б. Кустрин, А. Р. Король
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
